Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interferon-α1b (IFN-α1b) Combined With Toripalimab and Anlotinib Hydrochloride in Patients With Advanced Unresectable Melanoma

NCT05539118 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05539118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05539118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interferon-α1b (IFN-α1b) Combined With Toripalimab and Anlotinib Hydrochloride in Patients With Advanced Unresectable Melanoma
Lead sponsor
Xijing Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2022
Completion date
December 31, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma